These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 34024874)
1. To be Functional, or not to be Low in Cholesterol, that is the Clinical Concern when Evaluating Anti-Atherosclerotic Actions of High-Density Lipoproteins. Yoshida H J Atheroscler Thromb; 2021 Jul; 28(7):694-695. PubMed ID: 34024874 [No Abstract] [Full Text] [Related]
2. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory. Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738 [TBL] [Abstract][Full Text] [Related]
3. High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Srivastava RA; Srivastava N Mol Cell Biochem; 2000 Jun; 209(1-2):131-44. PubMed ID: 10942211 [TBL] [Abstract][Full Text] [Related]
4. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Shao B; Tang C; Sinha A; Mayer PS; Davenport GD; Brot N; Oda MN; Zhao XQ; Heinecke JW Circ Res; 2014 May; 114(11):1733-42. PubMed ID: 24647144 [TBL] [Abstract][Full Text] [Related]
5. Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. Morton AM; Koch M; Mendivil CO; Furtado JD; Tjønneland A; Overvad K; Wang L; Jensen MK; Sacks FM JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467335 [TBL] [Abstract][Full Text] [Related]
6. Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins. Martinez LO; Najib S; Perret B; Cabou C; Lichtenstein L Atherosclerosis; 2015 Jan; 238(1):89-100. PubMed ID: 25437896 [TBL] [Abstract][Full Text] [Related]
7. Antiinflammatory actions of HDL: a new insight. Rye KA; Barter PJ Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1890-1. PubMed ID: 18946054 [No Abstract] [Full Text] [Related]
12. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties]. Li M; Liu ZM Sheng Wu Gong Cheng Xue Bao; 2003 Jul; 19(4):387-91. PubMed ID: 15969051 [TBL] [Abstract][Full Text] [Related]
13. Dysfunctional HDL as a diagnostic and therapeutic target. Smith JD Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):151-5. PubMed ID: 19679832 [TBL] [Abstract][Full Text] [Related]
14. [High-density lipoproteins: the "new" target of cardiovascular medicine]. Sampietro T; Bigazzi F; Dal Pino B; Puntoni M; Bionda A Ital Heart J Suppl; 2005 Jun; 6(6):341-53. PubMed ID: 16013425 [TBL] [Abstract][Full Text] [Related]
15. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Rohrer L; Hersberger M; von Eckardstein A Curr Opin Lipidol; 2004 Jun; 15(3):269-78. PubMed ID: 15166782 [TBL] [Abstract][Full Text] [Related]
16. [Molecular Mechanism and Evaluation Method for Anti-Inflammatory HDL]. Tanaka N; Ishida T Rinsho Byori; 2016 Jan; 64(1):49-56. PubMed ID: 27192797 [TBL] [Abstract][Full Text] [Related]
17. Function of different proportions of apolipoprotein A-I cysteine mutants and apolipoprotein A-V on recombinant high-density lipoproteins Yan Y; Lu S; Jia S; Dong Q; Wang L; Wang Y Biosci Rep; 2019 May; 39(5):. PubMed ID: 31023964 [TBL] [Abstract][Full Text] [Related]